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Abstract Sanfilippo disease (mucopolysaccharidosis type
III, MPS III) is a severe metabolic disorder caused by
accumulation of heparan sulfate (HS), one of glycosami-
noglycans (GAGs), due to a genetic defect resulting in a
deficiency of GAG hydrolysis. This disorder is character-
ized as the most severe neurological form of MPS,
revealing rapid deterioration of brain functions. Among
therapeutic approaches for MPS III, one of the most
promising appears to be the substrate reduction therapy
(SRT). Genistein (5, 7-dihydroxy-3- (4-hydroxyphenyl)-
4H-1-benzopyran-4-one) is an isoflavone that has been
used in SRT for MPS III. In this report, we tested effects of
other flavonoids (apigenin, daidzein, kaempferol and
naringenin) on GAG synthesis. Their cytotoxicity and
anti-proliferation features were also tested. We found that
daidzein and kaempferol inhibited GAG synthesis signifi-
cantly. Moreover, these compounds were able to reduce
lysosomal storage in MPS IIIA fibroblasts. Interestingly,
although genistein is believed to inhibit GAG synthesis by
blocking the tyrosine kinase activity of the epidermal
growth factor receptor, we found that effects of other
flavonoids were not due to this mechanism. In fact,
combinations of various flavonoids resulted in signifi-
cantly more effective inhibition of GAG synthesis than
the use of any of these compounds alone. These results,
together with results published recently by others,
suggest that combination of flavonoids can be consid-





Mucopolysaccharidoses (MPS) are inherited metabolic
disorders, caused by mutations leading to dysfunction of
one of enzymes involved in degradation of glycosamino-
glycans (GAGs) in lysosomes (Beck 2007a; Neufeld and
Muenzer 2001). Depending on the nature of the deficient
enzyme, eleven types and subtypes of MPS are already
recognized. Partially degraded GAGs accumulate in cells of
MPS patients, causing dysfunction of tissues and organs,
including the heart, respiratory system, bones, joints and
central nervous system (CNS). In MPS types characterized
by the storage of heparan sulfate (HS), one of the GAGs,
neurological symptoms are among the most severe ones
(Neufeld and Muenzer 2001). Although enzyme replace-
ment therapy (ERT) has been developed for various types
of MPS, and registered to date for three of them (types I, II
and VI), such a treatment is ineffective for neurological
symptoms as the enzyme cannot cross the blood-brain-
barrier (for reviews, see Beck 2007a, b). The second
therapy used in a relatively large fraction of MPS patients,
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efficient to some extent in MPS type I, but not in MPS III
(Sanfilippo disease) (Beck 2007a, b), an MPS type
characterized by the most severe CNS dysfunctions among
mucopolysaccharidoses (for recent discussion, see Węgrzyn
et al. 2010).
Recently, 5, 7-dihydroxy-3- (4-hydroxyphenyl)-4H-1-
benzopyran-4-one), known also as genistein or 4′,5 ,7 -
trihydroxyisoflavone, has been demonstrated to be an
inhibitor of GAG synthesis in fibroblasts of patients
suffering from various types of mucopolysaccharidoses,
including MPS III (Piotrowska et al. 2006). Importantly, a
decrease in lysosomal GAG storage was noted after
incubation of the cells with genistein (Piotrowska et al.
2006). Subsequent studies indicated that genistein may be
effective in treatment of mice suffering from MPS IIIB (one
of four subtypes of MPS III) and MPS II, including
improvement in CNS in short-term treatment of animals
with the latter disease and complete correction of behavior
in long-term treatment of animals with the former disease
(Friso et al. 2010; Malinowska et al. 2009, 2010). In pilot
clinical studies, it was demonstrated that treatment of
patients suffering from MPS IIIA and MPS IIIB with a
genistein-rich isoflavone extract resulted in statistically
important improvement of all tested parameters (when
mean values from all patients were compared), including
cognitive functions, assessed by using a special psycholog-
ical test (Piotrowska et al. 2008). The effects of genistein on
neurological parameters in MPS animals and humans were
assumed to be due to an ability of this isoflavone to cross
the blood-brain-barrier, which was demonstrated previously
(Tsai 2005).
The mechanism of the genistein-mediated substrate
reduction therapy (SRT) was proposed to be due to
inhibition of phosphorylation of epidermal growth factor
receptor (EGFR) by this isoflavone (Jakobkiewicz-Banecka
et al. 2009). This therapeutic approach is promising
(Jakobkiewicz-Banecka et al. 2007), however, it is also
clear that further studies are necessary to optimize this
procedure. For example, Arfi et al. (2010) tested various
isoflavones for their activities in correction of GAG
lysosomal accumulation in MPS IIIA and MPS VII
fibroblasts, and found that some of the tested compounds
are as efficient as genistein in decreasing GAG storage in
MPS cells, and combination of different compounds from
this group may be more efficient than one single flavonoid.
Therefore, in this work we tested effects of some other
already known flavonoids—not only isoflavones (genistein
and daidzein, as studied by Arfi et al. 2010), but also a
flavone (apigenin), a flavonol (kaempferol) and a flavanone
(naringenin)—on GAG synthesis, considering that these
compounds might be potentially useful in optimization of
SRT for MPS.
Materials and methods
Cell lines, culture media, supplements and flavonoid
solutions
Skin fibroblasts obtained form MPS IIIA and MPS IIIB
patients (Piotrowska et al. 2009)w e r eu s e di na l l
experiments and Human Dermal Fibroblasts adult cell
line (Cascade Biologics, Portland, OR, USA) was used
as a healthy control line. Cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS) and 1×
Antibiotic and Antimycotic solution (all purchased from
Sigma, Germany) and incubated at 37°C in humidified
5% CO2 atmosphere. Minimal Essential Medium without
inorganic sulfates (MEM, Joklik’s modified, Sigma,
Germany) was used in GAG synthesis assay. Phosphate
Buffered Saline (PBS), dimethylsulfoxide (DMSO) and
dimethylformamide (DMF) were from Sigma (Germany).
Naringenin, daidzein, apigenin and kaempferol were
purchased from Sigma (Germany) and genistein was
synthesized at the Pharmaceutical Research Institute (War-
saw, Poland). Stock solutions of flavonoids were prepared
in dimethylformamide (DMF). MTT reagent (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
was dissolved in RPMI-1,640 medium without phenol
red (purchased from Sigma, Germany).
Cytotoxicity and proliferation assay
Cell viability was assessed with MTT assay. In brief, 6×
10
3 cells per well (in cytotoxicity assay) or 10
3 cells per
well (in proliferation assay) were seed in 96-well plates
and incubated overnight and than the growth medium was
substituted with fresh medium supplemented with tested
compounds at appropriate concentrations or 0.05% DMF
as a control (in cultures with tested compounds, DMF final
concentration was also adjusted to 0.05%). Following
incubation for 24 h (to test cytotoxicity) or for 7-days (to
test cell proliferation), medium was substituted with MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide) solution (1 mg/ml in RPMI-1640 medium) and after
2-h incubation at 37°C the formazan product was
d i s s o l v e di nD M S Oa n da b s o r b a n c ew a sr e a da t5 5 0n m .
LC50 value (in cytotoxicity assay) or IC50 value (in
proliferation assay) was determined for each compound
in contrast to nontreated cultures (incubated with DMF
only).
Measurement of kinetics of GAG synthesis
Kinetics of GAG synthesis was analyzed by measurement of
35S incorporation into proteoglycans according to previously
2 Metab Brain Dis (2011) 26:1–8described procedure (Piotrowska et al. 2006)w i t hm i n o r
modifications. In brief, cells in a number of 2×10
4 per well
were plated in 48-well plates and incubated overnight.
Growth medium was substituted with medium supplemented
with tested flavonoids at appropriate concentrations or 0.05%
DMF as a control. Cells were incubated for 48-hours and next
labeled with 20 μCi/ml of H2[
35S]O4 (Hartmann Analytic
GmbH, Germany) in a growth medium without inorganic
sulfate (MEM, Joklik’s modified) mixed with standard
DMEM medium (1:1) suplemented with FBS and tested
compounds. Cells were grown for another 24 h, washed six
times with PBS, digested with 0.03% papain (prepared in
100 mM sodium acetate with 5 mM L-cysteine, pH 7.0)
(Merck, Germany) and
35S incorporation was measured in a
scintillation counter. DNA concentration in papain digested
samples was determined using Quant-iT™ PicoGreen®
dsDNA Reagent [Molecular Probes, Inc., Eugene, OR,
USA] according to the manufacturer’s protocol. Incorpora-
tion of
35S was calculated per DNA amount.
Electron microscopic studies
Cells were grown in 12-well plate in DMEM supplemented
with appropriate concentrations of tested compounds for
6 days, washed three times with PBS, fixed with 2.5%
glutaraldehyde, next fixed in 1% osmium tetroxide and 1%
potassium hexacyanoferrate(III). Following ethanol dehy-
dration cells were embedded in Epon 812 resin (Fluka,
Germany), cut on the utlramicrotom PowerTome XL and
contrasted in lead acetate and uranyl acetate. Transmission
electron microscopy studies were performed using a Philips
CM100 microscope and lysosome structure number was
determined.
Assessment of tyrosine kinase activity of EGF receptor
Tyrosine kinase activity of EGF receptor was assessed
using commercially available Cell-Based ELISA, Human
Phospho-EGF R (Y1068) Immunoassay (R&D Systems
Inc., Minneapolis, MN, USA). Cells were plated in a
number of 10
4 cells per well of 96-well plate and
incubated overnight. Growth medium was substituted
with medium supplemented with flavonoids or a potent
tyrosine kinase inhibitor PD168393 (Calbiochem, La
Jolla, CA, USA) in appropriate concentrations. Following
2-h incubation, Epidermal Growth Factor (BD Biosciences,
Bedford, MA, USA) at the concentration of 100 ng/ml
was added to each well for 15 min. in order to induce
EGF receptor autophosphorylation. Next, growth medium
was removed, cells were fixed with 4% formaldehyde in
PBS for 20 min. and following steps were performed
according to the protocol provided by the manufacturer
of the ELISA assay.
Statistical analysis
To test for the effects of different concentrations offlavonoids
on the number of lysosomal structures one-way ANOVAwas
performed. Tukey’s multiple comparisions test was used as a
post-hoc comparator. This test, and the t-Student two-tailed
test were used to assess effects of flavonoids and their
mixtures on GAG synthesis efficiency and on the kinase
activity of EGFR. All tests were performed using Statistica
8.0 [StatSoft, Poland] software with significance indicated
where p values were less than 0.05.
Results
Cytotoxic and antiproliferative activities of flavonoids
We have tested different natural flavonoids for their
activities as inhibitors of GAG synthesis, and thus, for
their potential use in SRT for MPS. Apart from genistein, a
previously investigated isoflavone, four compounds were
tested: apigenin (a flavone), daidzein (an isoflavone),
kaempferol (a flavonol) and naringenin (a flavanone) (see
Fig. 1 for their formulas).
Potential medicines should reveal low cytotoxicity and
acceptable antiproliferative activity, thus, we have tested
Fig. 1 Structural formulas of
natural flavonoids used in this
work: apigenin (a), daidzein (b),
kaempferol (c), naringenin (d)
and genistein (e)
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cytotoxicity, assessed as LC50, of all tested compounds
(Table 1). The LC50 value was >100 μM for each tested
compound, and estimation of exact values of this parameter
was not possible due to low solubility of flavonoids in
water (and thus in the cell culture medium). Moreover, all
compounds had the IC50 value higher than that of genistein
in the antiproliferative activity assay (Table 1). Since
genistein had been shown previously to be a relatively safe
compound for treatment of MPS in both animals and
human patients (Klein and King 2007; Malinowska et al.
2009; Piotrowska et al. 2008), we suggest that safety
features of the tested flavonoids maybe acceptable at this
stage of the study, though more detailed experiments,
including tests on animals, are necessary to prove their
safety for organisms.
Effects of flavonoids on GAG synthesis
Effects of flavonoids on GAG synthesis were tested in
cultures of fibroblasts. Various concentrations of flavonoids
were added to cell cultures and synthesis of GAGs was
measured by estimation of the amount of incorporated
precursor, [
35S]sulfate. This method was chosen as in
mammalian cells the incorporation of
35S from radioactive
Na2SO4 into macromolecules occurs almost exclusively
into GAGs (Kato et al. 1995). An inhibition of GAG
synthesis was found in the presence of all tested com-
pounds, though the most pronounced impairment of
production of GAGs was observed in the presence of
kaempferol, and statistically significant differences relative
to untreated cells were observed only for kaempferol,
daidzein and genistein (Fig. 2). Due to low solubility of
apigenin and genistein in water, these compounds could not
be tested at the concentration of 100 μM.
We have also tested effects of combinations of various
flavonoids at low concentration (10 μM) on GAG synthe-
sis. Interestingly, such combinations resulted in more
effective inhibition of GAG production relative not only
to particular compounds used at the same concentration
alone (Fig. 3), but also to particular compounds used at the
concentration as high as the sum of concentrations of all
tested flavonoids (compare Figs. 2 and 3). Therefore,
Fig. 2 Dose-dependent effects of natural flavonoids on kinetics of
glycosaminoglycan synthesis in fibroblasts presented as relative
35S
incorporation into GAGs after 3-day exposure to different concen-
trations of flavonoids [μΜ]. Labeling was conducted for 24 h with
20 μCi/ml H2[
35S]O4. Radioactivity of incorporated
35S was measured
in a scintillation counter, calculated per DNA amount [dpm/ng DNA],
and expressed as the percentage of control. 100% (bold solid line,
with SD indicated by bold dashed lines) corresponds to the relative
35S incorporation into control cells (from the cell culture treated with
0.05% dimethylformamide). The results presented are average values
obtained for five different cell lines with bars indicating standard
deviation. Statistical analysis was performed by using the Tukey post-
hoc test. Values of p<0.05 (*) or p<0.01 (**) are indicated
Table 1 Cytotoxic and antiproliferative activity of natural flavonoids.
Cytotoxicity is expressed as LC50 index value, i.e. concentration of the
tested drug [μM] that is lethal to 50% of cells in a culture exposed to
the drug for 24 h. Exact LC50 values could not be determined due to
low solubility of flavonoids, which prevented achievement of their
concentrations in cell cultures high enough to measure this parameter
precisely. Antiproliferative activity is expressed as IC50 index value, i.e.
concentration of the tested drug [μM] that causes 50% inhibition of cell
proliferation in a culture exposed to the drug for 7 days
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Fig. 3 Effects of mixtures of natural flavonoids (K—kaempferol, N—
naringenin, D—daidzein, G—genistein, at 10 μM concentration each) on
kinetics of glycosaminoglycan synthesis in fibroblasts. Relative
35S
incorporation into GAGs after 3-day exposure to mixtures of various
flavonoids is presented. Labeling was conducted for 24 h with 20 μCi/ml
H2[
35S]O4. Radioactivity of incorporated
35S was measured in a
scintillation counter, calculated per DNA amount [dpm/ng DNA], and
expressed as the percentage of control (ctrl = cell culture treated with
0.05% dimethylformamide). The results presented are average values
obtained for three different cell lines with bars indicating standard
deviation. Statistical analysis was performed by using the t-Student two-
tailed test. Values of p<0.05 (*) or p<0.01 (**) are indicated
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GAG synthesis can be assumed.
Decreased lysosomal storage in the presence of flavonoids
In the treatment of MPS patients, an actual level of
lysosomal storage rather than kinetics of GAG synthesis is
crucial. Therefore, we have tested effects of flavonoids on
changes in lysosomal storage in MPS IIIA fibroblasts. To
assess the storage, we used electron microscopic techni-
ques, as described previously (Jakobkiewicz-Banecka et al.
2009; Piotrowska et al. 2006). Examples of abnormal
(stored) structures, occurring in MPS IIIA cells, are
presented in Fig. 4.
The fibroblasts were cultured in the absence and
presence of various flavonoids, and the abnormal structures
were observed under electron microscope and counted. We
observed a significant decrease in the number of various
abnormal structures in MPS IIIA cells after treatment of the
cultures with apigenin, daidzein, kaempferol and naringenin
(Table 2). Therefore, we conclude that all tested compounds
are effective in elimination of lysosomal storage from MPS
cells, despite the fact that only some of these flavonoids
(daidzein and kaempferol) caused statistically significant
inhibition of GAG synthesis, while the levels of the
inhibition by apigenin and naringenin did not reach
statistical significance (compare Table 2 and Fig. 2).
Effects of flavonoids on the phosphorylation of epidermal
growth factor receptor
Results of previous studies suggested that genistein impairs
GAG synthesis due to its inhibitory effect on the kinase
activity of the epidermal growth factor receptor (EGFR).
Thus, it was proposed that in the presence of genistein the
EGFR is underphosphorylated, which correlates with
impaired expression of genes coding for enzymes required
for GAG synthesis (Jakobkiewicz-Banecka et al. 2009).
To test whether tested flavonoids impair GAG synthesis
by the same mechanism as that proposed for genistein, we
have measured efficiency of phosphorylation of EGFR in
the presence and absence of investigated flavonoids.
However, we found that contrary to genistein and a
synthetic inhibitor of the tyrosine kinase—PD168393 (used
as an additional positive control), none of the tested
flavonoids revealed statistically significant inhibiton of
EGFR phosphorylation (Fig. 5). Therefore, it appears that
these compounds impair GAG synthesis by the meachan-
ism different from that identified for genistein.
Discussion
Substrate reduction therapy has recently been shown to be a
promising strategy for treatment of neuronopathic forms of
mucopolysaccharidoses and other lysosomal storage dis-
eases (Jakobkiewicz-Banecka et al. 2007). This therapeut-
ical strategy is based on the use of relatively small
molecules, including drugs that may cross the brain-
blood-barrier and act in the central nervous system. Studies
on MPS II and MPS III, the MPS types in which the
neurological symptoms are severe or extremely severe,
respectively, indicated that genistein, a natural isoflavone,
can be effective in treatment of some symptoms, including
behavior and cognitive abilities, in both mouse models and
human patients (Friso et al. 2010; Malinowska et al. 2009,
2010; Piotrowska et al. 2008). Nevertheless, efficiency of
this treatment was not high enough to cure all symptoms in
patients, therefore, searching for possibilities to improve







Fig. 4 Different lysosomal structures observed in fibroblasts of the
MPS IIIA patient. Electron microphotographs present: lysosome of
lamellar and electron-dense structures (a), lysosome of amorphous,
flocculent and electron-lucent structures (b), and complex lysosomal
structure (autophagolysosome) with storage material of different
electron density (c)
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of GAG synthesis could be the use of the siRNA
technology to silence genes responsible for expression of
enzymes involved in GAG production, as proposed recently
(Dziedzic et al. 2009; Kaidonis et al. 2009). However, the
current procedures of delivery of siRNA to central nervous
system are not efficient enough to ensure effective
treatment.
Another option would be to use different compounds
that can inhibit GAG synthesis. Roberts et al. (2006, 2007)
demonstrated that rhodamine B is an effective inhibitor of
GAG production in vitro and in vivo (in the MPS IIIA
mouse model). However, the toxicity profile of rhodamine
B appears to be not acceptable for its use as a drug for
humans (Roberts et al. 2006; Roberts et al. 2007). Although
recent studies suggest that a long-term treatment with low
doses of rhodamine B is safe for mice (Roberts et al. 2010),
it is not clear whether the safety profile is the same for
humans and whether treatment with such low doses may be
effective in alleviation of MPS symptoms. Therefore, we
search for other compounds that might be effective in
treatment of MPS.
Flavonoids, as compounds relative to genistein that has
been demonstrated previously to be an inhibitor of GAG
synthesis (Piotrowska et al. 2006), are natural candidates
for drugs able to manage neurological symptoms of MPS.
Table 2 Quantitative analysis of lysosomal structures in MPS IIIA fibroblasts exposed to different concentrations of flavonoids for 6 days. Mean
numbers of lysosomal structures per 100 μm
2 of cell cross-section with standard deviation are presented
Flavonoid (μM) Number of lysosomal structures per 100 μm
2 of cell cross-section ± SD
Lamellar Complexed (autophago-lysosomes) Amorphous Total number
Control (DMF) 0.40±0.17 0.35±0.35 0.38±0.27 1.13±0.50
Apigenin (30) 0.22±0.18*# 0.15±0.10* 0.14±0.13* 0.51±0.24*
Apigenin (100) 0.08±0.06*# 0.20±0.10 0.13±0.18* 0.41±0.18*
Daidzein (30) 0.13±0.12* 0.12±0.10* 0.15±0.11* 0.40±0.19*
Daidzein (100) 0.22±0.13* 0.32±0.15 0.16±0.09* 0.70±0.24*
Kaempferol (30) 0.21±0.12* 0.36±0.10 0.07±0.05* 0.63±0.15*
Kaempferol (100) 0.27±0.26 0.32±0.13 0.09±0.06* 0.68±0.27*
Naringenin (30) 0.29±0.15 0.19±0.10 0.39±0.22# 0.87±0.40
Naringenin (100) 0.21±0.17* 0.16±0.14* 0.19±0.11# 0.56±0.23*
Statistically significant differences (Tukey’s post-hoc test; p<0.05) between control (untreated MPS IIIA cells) and treated cells are indicated with
asterisks and significant differences (Tukey’s post-hoc test; p<0.05) between two concentrations of the tested compound are indicated with hash
marks
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Fig. 5 Effects of flavonoids (at different concentrations) on tyrosine
kinase activity of EGF receptor (EGFR). The results of phospho-
EGFR fluorescence were normalized to the total EGFR fluorescence
and presented as the percentage of the control cells (incubated without
flavonoids). Abbreviations are as follows: K—kaempferol, D—
daidzein, N—naringenin, G—genistein, I—a potent EGFR tyrosine
kinase inhibitor, PD168390 (which was used as an additional positive
control). The results presented are average values obtained from two
different experiments with bars indicating standard deviation. Statis-
tically significant differences (p<0.05) are marked by asterisk
6 Metab Brain Dis (2011) 26:1–8Therefore, we have tested effects of four different flavo-
noids in assays for GAG synthesis, lysosomal structures
and phosphorylation of EGFR. In addition, their cytotox-
icity and proliferation inhibition activity were tested.
Our studies revealed that apigenin (a flavone), daidzein
(an isoflavone), kaempferol (a flavonol) and naringenin (a
flavanone) caused a decrease in the efficiency of GAG
synthesis, though only daidzein and kaempferol caused
statistically significant differences relative to untreated
cells. Nevertheless, in the presence of all these compounds,
lysosomal storage in MPS IIIA fibroblasts was significantly
decreased. Since all the tested flavonoids, when used at
moderate (up to 30 or 100 μM, depending on the solubility
of the compound) concentrations, revealed acceptable
profiles in cytotoxicity and proliferation inhibition assays,
either in MPS-derived cells (this report) or normal cells
(Matsuo et al. 2005; Li et al. 2008; Kwack et al. 2009), it
appears that they can be considered as potential drugs.
Obviously, further tests, including those with animal
models, are necessary to prove their safety for organisms.
Interesting results were obtained when combinations of
various flavonoids at their low concentration (10 μM) were
tested. Many such combinations appeared to be more
effective in GAG synthesis inhibition than particular
compounds tested separately, even when total flavonoid
concentrations were the same. A report by Arfi et al. (2010)
has been published recently, in which various isoflavones
(daidzein, glycitein, formononetin, prunetin and biochanin)
were tested for their activities in correction of GAG
lysosomal accumulation in MPS IIIA and MPS VII
fibroblasts. Although different methods of estimation of
efficiency of these compounds in regulation of GAG
metabolism were used by us (this report) and by Arfi et
al. (2010), similar conclusions can be drawn from both
studies. Namely, some flavonoids (e.g. kaempferol and
various isoflavones) are as efficient as genistein in
decreasing GAG storage in MPS cells, and combination
of different compounds from this group may be more
efficient than one single flavonoid. The latter conclusion
appears to be reasonable in the light of our results
indicating that flavonoids tested in this work (daidzein,
kaempferol and naringenin) inhibit GAG synthesis by a
mechanism different from that demonstrated for genistein.
Namely, contrary to genistein, other flavonoids were not
effective in inhibition of EGFR phosphorylation. Although
the exact mechanism(s) of their action as GAG synthesis
inhibitors remain(s) to be elucidated, differences in means
by which various flavonoids impair GAG production may
explain their synergistic effects when they were used in
mixtures.
Knowing the mechanism of genistein-mediated inhibi-
tion of GAG synthesis, which likely depends on inhibition
of EGFR autophosphorylation (Jakobkiewicz-Banecka et
al. 2009), one might propose that other EGFR tyrosine
kinase inhibitors can be considered as putative drugs in
MPS treatment. However, there are serious problems with a
potential use of such inhibitors in therapies for children
suffering from MPS. First, synthetic compounds influenc-
ing activities of tyrosine kinases are generally strong
inhibitors (Sherman 2009; Takeuchi and Ito 2010), while
GAGs are compounds necessary for development and
proper functions of many tissues and organs (Bulow and
Hobert 2006; Li and Richards 2010), thus, complete or very
strong inhibition of their production would not be desired,
especially in children. Second, SRT for inherited metabolic
diseases, like MPS, must be considered as a long-term
therapy, potentially for the whole life. Since there are
various toxic and/or adverse effects of synthetic inhibitors
of tyrosine kinases reported in literature, including effects
on thyroid function and thyroid hormone metabolism
(Sherman 2009), diarrhea (Medina and Goodin 2008;
Sanford and Scott 2009), nausea (Medina and Goodin
2008), skin toxicity (Li and Perez-Soler 2009), and cardiac
toxicity(manifestedascongestiveheartfailure)(deAzambuja
et al. 2009; Medina and Goodin 2008), their use in treatment
of MPS patients for many years appears rather unlikely.
Therefore, the use of natural flavonoids, which are relatively
weak inhibitors of GAG synthesis with marginal, if any,
adverse effects, could be one of the most promising options
for SRT in MPS.
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